This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hurel, S. J. Articles by Baylis, P. H. Search for Related Content PubMed PubMed Citation Articles by Hurel, S. J. Articles by Baylis, P. H.

Metastatic Prolactinoma: Effect of Octreotide, Cabergoline, Carboplatin and Etoposide; Immunocytochemical Analysis of Proto-Oncogene Expression

Department of Medicine (S.J.H., S.F., P.H.B.), Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP; Department of Medicine (P.E.H.), Kings College Medical School, London, SE5 9TJ; Department of Medicine (W.F.K.), Middlesbrough General Hospital, Middlesbrough, TS5 5AZ; and University Department of Pathology (A.M.M.), Glasgow Royal Infirmary, Glasgow, G4 OSF

Address correspondence and requests for reprints to: S.J. Hurel, Department of Medicine, Royal Victoria Infirmary, Queen Victoria Road, Farmington Place, Newcastle-Upon-Tyne, United Kingdom NE1 4LP.

A 49-yr-old woman presented with an extensive prolactinoma (serum PRL > 10,000 mU/L, normal range <450 mU/L). Over a 5-yr period following transsphenoidal surgery and pituitary irradiation, she became increasingly resistant to high doses of bromocriptine and underwent transfrontal surgery followed by stereotactic radiotherapy. In spite of these treatments, serum prolactin estimations rose progressively to >100,000 mU/L. Magnetic resonance imaging scanning demonstrated a massive cystic tumor invading the temporal lobes, extending into the cervical and thoracic spine, with metastases to cervical lymph nodes. High-dose cabergoline administration resulted in a 30% decrease in serum PRL. Octreotide was administered as a continuous sc infusion with a profound analgesic effect on facial pain but with no effect on tumor progression. She was treated with a course of chemotherapy consisting of carboplatin and etoposide without any noticeable effect. The patient died 6 months following chemotherapy. Immunocytochemical analysis demonstrated positive nuclear staining for WAF-1, Rb protein, c-myc, and p53 both in the original and metastatic tumors. The metastases but not the primary tumor stained for c-jun. Metastatic prolactinoma remains a therapeutic challenge. It is associated with a variable proto-oncogene expression, which may be coincidental or causal. Cabergoline had no advantage over bromocriptine. Octreotide relieved facial pain but did not alter tumor progression. An effective therapy for metastatic prolactinoma remains to be identified.

This article has been cited by other articles:

				M. Kars, F. Roelfsema, J. A Romijn, and A. M Pereira Malignant prolactinoma: case report and review of the literature. Eur. J. Endocrinol., October 1, 2006; 155(4): 523 - 534. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]

				K. N. Farrow, A. P. Bradford, J. J. Tentler, and A. Gutierrez-Hartmann Structural and Functional Analysis of the Differential Effects of c-Jun and v-Jun on Prolactin Gene Expression Mol. Endocrinol., October 1, 2004; 18(10): 2479 - 2490. [Abstract] [Full Text] [PDF]

				P. Petrossians, W. De Herder, D. Kwekkeboom, G. Lamberigts, A. Stevenaert, and A. Beckers Malignant Prolactinoma Discovered by D2 Receptor Imaging J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 398 - 401. [Full Text]

				Y. Cheng, I. Zhizhin, R. L. Perlman, and D. Mangoura Prolactin-induced Cell Proliferation in PC12 Cells Depends on JNK but Not ERK Activation J. Biol. Chem., July 21, 2000; 275(30): 23326 - 23332. [Abstract] [Full Text] [PDF]